Dogwood Therapeutics (DWTX) Non-Current Assets (2024 - 2026)

Dogwood Therapeutics has reported Non-Current Assets for 3 years, with the latest figure at $69.5 million in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 15.27% year-over-year to $69.5 million in Q2 2026; TTM through Jun 2026 was $311.8 million, a 31.22% increase from a year earlier, with the FY2025 full-year figure at $81.7 million, up 5.11% from the prior year.
• Non-Current Assets was $69.5 million for Q2 2026 at Dogwood Therapeutics, down from $80.2 million in the prior quarter.
• The five-year high for Non-Current Assets was $82.0 million in Q2 2025, with the low at $69.5 million in Q2 2026.
• Average Non-Current Assets over 3 years is $78.5 million, with a median of $80.2 million recorded in 2026.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets rose 5.11% in 2025, then decreased 15.27% in 2026.
• Over 3 years, Non-Current Assets stood at $77.8 million in 2024, then increased by 5.11% to $81.7 million in 2025, then dropped by 15.01% to $69.5 million in 2026.
• The last three Non-Current Assets figures came in at $69.5 million (Q2 2026), $80.2 million (Q1 2026), and $81.7 million (Q4 2025), per Business Quant data.